EAST HILLS, N.Y.--(BUSINESS WIRE)--The increasing focus on biotechnology and personalized medicines along with the growth of the vaccine marketplace is changing the face of the biopharmaceutical industry, an $80 billion global market. Drug manufacturers are challenged by cost pressures, the need for shorter production times and rapid scale-up, as well as bottlenecks in downstream operations. At INTERPHEX2007, Pall Corporation (NYSE:PLL) launches several new technologies to provide the biopharmaceutical industry with tools and systems to more efficiently manage their manufacturing processes. A leader in filtration, separation and purification, Pall offers a comprehensive line of integrated solutions for biopharmaceutical manufacturers from upstream to downstream applications.
